Southeast Netherlands Advanced Metastatic Breast Cancer Registry
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorAcademisch Ziekenhuis Maastricht
About this trial
The Southeast Netherlands Advanced Breast Cancer (SONABRE) Registry is a real life multi-center study. The registry aims to include all patients diagnosed with advanced breast cancer as of 2007 in 11 hospitals in the Netherlands. Data on patient, tumor and treatment characteristics are collected retrospectively from electronic medical files by trained registry clerks.
Eligibility criteria
Qualifiers
Diagnosed with de novo or recurrent advanced breast cancer since 2007
Diagnosed with or treated for advanced breast cancer in one of the participating hospitals
Participating hospitals (period of inclusion): Maastricht UMC+ (2007-2025), Zuyderland hospitals Sittard/Heerlen (2007-2025), Amphia Hospital Breda (2013-2025), Catharina Hospital Eindhoven (2007-2025), Elkerliek Hospital Helmond (2010-2025), Maxima Medical Center Veldhoven/Eindhoven (2007-2025), Jeroen Bosch Hospital Den Bosch (2013-2025), Laurentius Hospital Roermond (2007-2025), St. Annaziekenhuis Geldrop (2007-2025), St. Elisabeth Hospital Tilburg (2007-2009), St. Jans Gasthuis Weert (2007-2025), VieCuri Medical Center Venlo/Venray (2013-2025), all in the Netherlands.
Hospitals (and periods) were eligible for inclusion if (distant) registration from Maastricht UMC+ was possible.
Disqualifiers
None
Trial design
Treatments tested in this trial
- Not listed
Trial groups
No trial groups listed
Sponsors and collaborators
Academisch Ziekenhuis Maastricht
Lead sponsor
Novartis
Collaborator
Pfizer
Collaborator
Roche Pharma AG
Collaborator
Eli Lilly and Company
Collaborator
ZonMw: The Netherlands Organisation for Health Research and Development
Collaborator
Eisai Inc.
Collaborator
Daiichi Sankyo
Collaborator
AstraZeneca
Collaborator
Gilead Sciences
Collaborator
Source ClinicalTrials.gov